CJC-1295 (NO DAC)

Chemical Makeup:

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.9 g/mol
• Synonyms: Mod GRF 1-29, Tetrasubstituted GRF (1-29)

Sequence:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

[CJC-1295 (NO DAC)] and Growth Hormone Secretion

In biological assays involving murine models, the administration of CJC-1295 (NO DAC) has been observed to stimulate a significant increase in plasma Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1) levels. Research indicates that the peptide preserves the natural episodic pattern of GH release, which is critical for maintaining receptor sensitivity. Studies utilizing radioimmunoassay techniques have demonstrated a dose-dependent elevation in basal GH concentrations following subcutaneous administration in test subjects.

[CJC-1295 (NO DAC)] and Protein Synthesis

Experimental data suggests a correlation between GHRH analogues and enhanced nitrogen retention. In controlled animal studies, subjects exposed to pulsatile GHRH stimulation exhibited markers consistent with increased protein synthesis and cellular hyperplasia (muscle fiber splitting). The pathway is believed to be mediated through the downstream hepatic release of IGF-1, which facilitates amino acid uptake in skeletal muscle tissue.

[CJC-1295 (NO DAC)] and Lipolysis

Metabolic research conducted on obese rodent models has investigated the role of GHRH analogues in adipose tissue oxidation. Findings suggest that CJC-1295 (NO DAC) may influence the breakdown of triglycerides into free fatty acids (lipolysis). It has been hypothesized that this action is distinct from adrenergic pathways, offering a potential avenue for research into metabolic regulation without inducing significant spikes in cortisol or insulin.

[CJC-1295 (NO DAC)] and Sleep Architecture

Investigations into the neuroendocrinology of GHRH analogues imply a role in the regulation of Slow-Wave Sleep (SWS). In rat models, intracerebroventricular administration of GHRH agonists has been linked to an increase in non-REM sleep duration. It is postulated that the feedback loop involving GHRH and somatostatin contributes to the consolidation of deep sleep cycles, which are essential for neurogenic recovery and memory processing.

If you're not 100% satisfied within the first 30 days, just send it back to us and we'll give you a full refund.

No need to worry about the return shipping - we've got you covered!

We offer fast and reliable shipping on all orders. You can expect to receive it within 7-12 business days based on your location.

Please contact our customer service team for assistance if you have any questions or concerns about your shipment.

Adverse Research Observations: 

In animal toxicology studies, side effects noted during the administration of GHRH analogues included transient vasodilation (flushing) and mild injection site irritation. Excessive dosing in test subjects has been linked to water retention and potential desensitization of the pituitary axis, although the pulsatile nature of the NO DAC variant theoretically mitigates the risk of somatotroph downregulation compared to continuous-release formulations.

Withdrawal: 

No evidence of physical dependence or withdrawal symptoms has been recorded in cessation studies involving non-human primates. Physiological GH levels typically return to baseline parameters shortly after the discontinuation of the research protocol.

DISCLAIMER: RESEARCH USE ONLY 

This product is intended exclusively for laboratory research and development purposes. It is not intended for human consumption, diagnostic, therapeutic, or clinical use. The information provided is for educational and reference purposes only. Purchase of this product is restricted to qualified research institutions and certified professionals.